DYN
Dyne Therapeutics Inc
NASDAQ: DYN · HEALTHCARE · BIOTECHNOLOGY
$17.41
-4.13% today
Updated 2026-04-29
Market cap
$2.88B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.47
Dividend yield
—
52W range
$8 – $25
Volume
2.2M
Dyne Therapeutics Inc (DYN) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $341.00M | $319.00M | $135.00M | $423.00M | $-20.00M | $-44.00M | $175.00M | $-62.00M | $94.00M | $676.00M | $585.00M | $-4.16M | $-11.83M | $-46.51M | $-119.56M | $-153.65M | $-188.16M | $-292.37M | $-403.21M |
| Capital expenditures | $0.00 | $0.00 | $0.00 | $333.00M | $242.00M | $0.00 | $98.00M | $0.00 | $275.00M | $326.00M | $224.00M | $134000.00 | $1.65M | $1.16M | $3.62M | $3.07M | $729000.00 | $2.38M | $1.92M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $-522.00M | — | — | — | — | — | $15.00M | $19.00M | $28.00M | $31.00M | $44.00M | $1000.00 | $26000.00 | $6.59M | $17.54M | $15.18M | $19.97M | $45.86M | $45.85M |
| Free cash flow | $341.00M | $319.00M | $135.00M | $90.00M | $-262.00M | $-44.00M | $77.00M | $-62.00M | $-181.00M | $350.00M | $361.00M | $-4.30M | $-13.48M | $-47.67M | $-123.18M | $-156.71M | $-188.89M | $-294.75M | $-405.13M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | $23.00M | $22.00M | $22.00M | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |